Association of endocan expression with clinicopathological prognostic parameters in breast carcinoma

2021 ◽  
pp. 1-7
Author(s):  
Zeliha Esin Celik ◽  
Fatih Demir ◽  
Harun Yonar ◽  
Serdar Ugras
Keyword(s):  
Tumor Size ◽  
Carcinoma In Situ ◽  
Tumor Necrosis ◽  
Lobular Carcinoma ◽  
Prognostic Parameters ◽  
Lobular Carcinoma In Situ ◽  
Therapeutic Implications ◽  
The Relationship ◽  
Common Malignancy

BACKGROUND: Breast cancer (BC) is a common malignancy in women. Some molecules, including endocan, are still under investigation as potential prognostic factors in BC. OBJECTIVE: In the present study, we aimed to determine the relationship between endocan expression and clinicopathological prognostic parameters in BC. METHODS: Two hundred and fifty-five patients diagnosed with BC were included in the present study. The immuno-reactivity scoring (IRS) system was used to reveal the tissue endocan expression levels. RESULTS: We found that endocan expression is associated with tumor necrosis, tumor size, and the presence of lobular carcinoma in situ (LCIS) in BC. There was no relationship between endocan expression and survival as well as other clinicopathological prognostic parameters. CONCLUSION: Endocan overexpression in BC is associated with some prognostic parameters, including tumor necrosis, tumor size, and the presence of LCIS. Further studies with larger series are needed to reveal the clinical and therapeutic implications of endocan in BC.

The Pathologic Finding of Combined Lobular Carcinoma in Situ and Invasive Lobular Cancer May Indicate more than Just a High-Risk Marker Role of Lobular Carcinoma in Situ

2017 ◽  
Vol 83 (5) ◽  
pp. 482-485
Author(s):  
Christopher J. Jean-Louis ◽  
Joshua Masdon ◽  
Betsy Smith ◽  
Oscar Battles ◽  
Paul Dale
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Tumor Size ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Risk Marker ◽  
Mixed Group ◽  
Lobular Carcinoma In Situ

For years, lobular carcinoma in situ (LCIS) has been considered a high-risk marker for developing breast cancer. It is well known that ductal carcinoma in situ is a precursor for the development of invasive ductal carcinoma, and ductal carcinoma in situ is reported to be present in invasive ductal carcinoma in at least 40 per cent of cases. A similar relationship between LCIS and invasive lobular carcinoma (ILC) remains in question. This study evaluates the incidence of synchronous LCIS and ILC at our institution. This is a retrospective review of our tumor registry database of women diagnosed with LCIS or ILC from 2000 to 2014. Pathology reports were evaluated to determine the incidence of pure ILC and mixed ILC/LCIS. Those with both LCIS/ILC (mixed group) and those with pure ILC (pure group) were compared for age, surgical intervention, lymph node involvement, tumor size, nuclear grade, and margins between these two groups. A total of 182 women were identified with LCIS, ILC, or mixed LCIS and ILC. There were76 subjects with pure ILC and 90 with mixed LCIS and ILC. The median and age range for each group were 63.6 (range: 40–97) for the mixed and 64.1 (range: 40–86) for pure groups. Tumor size was evaluated for each group and the median tumor size was 2.5 cm (range: 0.1–7.0cm) for the mixed group and 3.0 cm (range: 0.5–12.5 cm) for the pure group. Nodal involvement was present in 35.23 per cent of the mixed group and 46.3 per cent in the pure group. Surgical treatment for each group was similar, with mastectomy being the preferred surgical option over breast conservation therapy in the mixed and pure groups, 67.07 and 64.71 per cent, respectively. Presently, LCIS is considered a marker, or risk factor, for development of future breast cancer. This retrospective study does identify a strong relationship, 54 per cent, between LCIS and ILC at diagnosis. This high percentage of concurrent LCIS and ILC in surgical/ pathological specimens supports the notion that LCIS may in fact have a precursory role in development of invasive lobular carcinoma of the breast. Additional studies to further investigate this relationship between LCIS and ILC, including genomic analysis, are presently underway.

Current guidelines on the diagnosis and management of lobular carcinoma in situ

2017 ◽  
Vol 15 (1) ◽  
pp. 87-90
Author(s):  
Ewa Śrutek ◽  
◽  
Tomasz Nowikiewicz ◽  
Wojciech Zegarski ◽  
◽  
...  
Keyword(s):  
Carcinoma In Situ ◽  
Lobular Carcinoma ◽  
Lobular Carcinoma In Situ ◽  
Diagnosis And Management ◽  
Current Guidelines

Lobular carcinoma in situ of the breast within a fibroadenoma. A case report

2004 ◽  
Vol 94 (2) ◽  
pp. 572-574 ◽  
Author(s):  
Vania Stafyla ◽  
Nikolaos Kotsifopoulos ◽  
Kyriakos Grigoriades ◽  
George Kassaras ◽  
George H Sakorafas
Keyword(s):  
Case Report ◽  
Carcinoma In Situ ◽  
Lobular Carcinoma ◽  
Lobular Carcinoma In Situ

scholarly journals Clonal relationships between lobular carcinoma in situ and other breast malignancies

2016 ◽  
Vol 18 (1) ◽  
Author(s):  
Colin B. Begg ◽  
Irina Ostrovnaya ◽  
Jose V. Scarpa Carniello ◽  
Rita A. Sakr ◽  
Dilip Giri ◽  
...  
Keyword(s):  
Carcinoma In Situ ◽  
Lobular Carcinoma ◽  
Lobular Carcinoma In Situ ◽  
Breast Malignancies

Ductal and lobular carcinoma in situ arising within an enlarging biopsy proven fibroadenoma

2021 ◽  
Vol 14 (1) ◽  
pp. e237017
Author(s):  
Yara Z Feliciano ◽  
Rochelle Freire ◽  
Jose Net ◽  
Monica Yepes
Keyword(s):  
Needle Biopsy ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Incidental Finding ◽  
Case Reports ◽  
Lobular Carcinoma ◽  
Lobular Carcinoma In Situ ◽  
Current Case ◽  
Malignant Changes

The diagnosis via core needle biopsy of concurrent ductal carcinoma in situ and lobular carcinoma in situ within an enlarging previously biopsied benign fibroadenoma in women in their 40s is rare. Several case reports have described the occurrence of malignant changes within fibroadenomas, usually as an incidental finding following excision, and few reports have documented the transition of a fibroadenoma to malignancy. The current case report emphasises the importance of re-biopsying enlarging fibroadenomas, even with otherwise maintained benign appearing features on imaging, in women in their 40s, in order to exclude the possibility of malignancy.

Lobular carcinoma in situ of the breast Detailed analysis of 99 patients with average follow-up of 24 years

1978 ◽  
Vol 2 (3) ◽  
pp. 225-252 ◽  
Author(s):  
Paul Peter Rosen ◽  
Philip H. Lieberman ◽  
David W. Braun ◽  
Cynthia Kosloff ◽  
Frank Adair
Keyword(s):  
Detailed Analysis ◽  
Carcinoma In Situ ◽  
Lobular Carcinoma ◽  
Lobular Carcinoma In Situ
Sign in / Sign up

Export Citation Format

Share Document